Chemistry:Fezakinumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | IL-22 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6408H9873N1706O2016S44 |
| Molar mass | 144479.04 g·mol−1 |
  (what is this?) (verify) | |
Fezakinumab is a human monoclonal antibody against interleukin-22,[1] designed for the treatment of psoriasis and rheumatoid arthritis.[2]
Research and development
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis,[3] but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis.[4]
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Fezakinumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/fezakinumab.pdf.
- ↑ "Pfizer Pipeline". 28 February 2011. http://www.pfizer.com/files/research/pipeline/2011_0228/pipeline_2011_0228.pdf.
- ↑ "Emerging Parenteral Biologic Therapies for Rheumatoid Arthritis". Living Medical eTextbook - Rheumatology - Projects In Knowledge. p. 4. http://lmt.projectsinknowledge.com/Activity/index.cfm?showfile=b&jn=2016&sj=2016.05&sc=2016.05.4.
- ↑ "Atopic dermatitis: fezakinumab shows benefit in severe disease". Aptus Health. http://quantiamd.univadis.com/player/yfprpshwk?u=bhabzahbt.
 |  |
